Correspondence on “ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)” by Miller et al
Authors:
- 1 March 2022
- journal article
- letter
- Published by Elsevier in Genetics in Medicine
- Vol. 24 (3) , 744-746
Abstract
No abstract availableAll Related Versions
Funding Information
- Medical Research Council
- British Heart Foundation (RE/18/4/34215, RG/19/6/34387)
- NIHR Imperial Biomedical Research Centre
- Wellcome Trust (107469/Z/15/Z, 200990/A/16/Z)
This publication has 10 references indexed in Scilit:
- Phenotypic Expression and Outcomes in Individuals With Rare Genetic Variants of Hypertrophic CardiomyopathyJACC, 2021
- Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG)Genetics in Medicine, 2021
- ACMG SF v3.0 list for reporting of secondary findings in clinical exome and genome sequencing: a policy statement of the American College of Medical Genetics and Genomics (ACMG)Genetics in Medicine, 2021
- Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the TTN GeneCirculation: Heart Failure, 2020
- Titin Truncating Variants in Adults Without Known Congestive Heart FailureJACC, 2020
- A mutation update for the FLNC gene in myopathies and cardiomyopathiesHuman Mutation, 2020
- Genomics-First Evaluation of Heart Disease Associated With Titin-Truncating VariantsCirculation, 2019
- FLNC pathogenic variants in patients with cardiomyopathies: Prevalence and genotype‐phenotype correlationsClinical Genetics, 2019
- Phenotype and Clinical Outcomes of Titin CardiomyopathyJACC, 2017
- Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic CardiomyopathiesJACC, 2016